Can a cancer drug spray stop debilitating nosebleeds?
NCT ID NCT02157987
First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time
Summary
This trial tests whether a nasal spray containing bevacizumab, a drug typically used for cancer, can reduce frequent nosebleeds in people with hereditary hemorrhagic telangiectasia (HHT). The study enrolls 20 adults who have at least 10 nosebleeds per month. The goal is to see if the spray can cut the number of monthly nosebleeds by at least half.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- bevacizumab nasal spray
- What this could lead to
- If it works, this could offer a simple, non-surgical way to control frequent nosebleeds in people with HHT, improving quality of life.
- What could go wrong
- This is an early-phase trial with only 20 participants, so results may not apply broadly. The spray's effectiveness and safety are still unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
20 people
The number who actually took part.
- Started
-
Dec 2014
- Finished
-
Dec 2021
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 70 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * patients with Rendu-Osler-Weber disease * patients with iterative epistaxis (at least 10 per month) * patients without treatment for 3 months with usual techniques (for the epistaxis) * patients speaking french fluently * patients with written consents * affiliation to social security * women with effective contraception during the treatment and for 6 months after stopping Exclusion Criteria: General criteria: * Pregnant women, breastfeeding * Hypersensitivity to the active substance or any of its excipients * Hypersensitivity to the products of Chinese hamster ovary cells or other human or humanized recombinant antibodies * Inability to undergo medical monitoring due to reasons geographical, social or psychological * Patient under guardianship * Patient included in another biomedical research protocol Related to medical history criteria: * Uncontrolled hypertension ( systolic BP \> or = 150 mmHg and / or Diastolic BP \> or = 100 mmHg) * Thrombocytopenia \<100 G / L * Taking NSAIDs within ten days prior to inclusion * Anticoagulant therapy or thrombolytic within 28 days before inclusion * Tumor, genetic predisposition to bleeding, coagulopathy , patient receiving treatment full anticoagulant dose for an event thromboembolism prior to inclusion * Major surgery within 28 days prior to inclusion * History of thromboembolic disease within 6 months prior to enrollment * Arteriovenous malformation localized to the brain, liver or lung on scanner older than 5 years * History of heart failure * Patients with proteinuria / creatinine greater than 2g / g
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Telangiectasia, hereditary hemorrhagic are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU de Caen
Caen, 14033, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.